[ORGANIZATION]
Scholar Rock
Featured in 3 tracked stories · first seen
Situations
FDA approval of ISEMBYLD for SMA
2 clusters · 7 sources · last updated
Latest: FDA approves apitegromabe to combat muscle loss in SMA patients
The U.S. Food and Drug Administration (FDA) has approved ISEMBYLD (apitegromab-mstn), developed by Scholar Rock, for the treatment of spinal muscular atrophy (SMA) in adults and children aged two years and older who are